LEXARIA BIOSCIENCE CORP. Adjustment for Long-term Intercompany Transactions, Tax Expense (Benefit)
LEXARIA BIOSCIENCE CORP. (LEXX) reported Adjustment for Long-term Intercompany Transactions, Tax Expense (Benefit) of $23.63 thousand for the 12-month period ending 2022-08-31, per its 10-K filed 2022-11-28.
Discontinued › Expense Statement › Income Tax
us-gaap:AdjustmentForLongTermIntercompanyTransactionsTaxExpenseBenefit · last filed 2022-11-28
- LEXARIA BIOSCIENCE CORP. adjustment for long-term intercompany transactions, tax expense (benefit) for fiscal 2022 was $23.63K.
- LEXARIA BIOSCIENCE CORP. adjustment for long-term intercompany transactions, tax expense (benefit) for fiscal 2021 was $0.00.
- LEXARIA BIOSCIENCE CORP. adjustment for long-term intercompany transactions, tax expense (benefit) for fiscal 2020 was $0.00.
- LEXARIA BIOSCIENCE CORP. adjustment for long-term intercompany transactions, tax expense (benefit) for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
| Period end | Adjustment for Long-term Intercompany Transactions, Tax Expense (Benefit) 12 month |
|---|---|
| 2022-08-31 | $23.63K 10-K · filed 2022-11-28 |
| 2021-08-31 | $0.00 10-K · filed 2022-11-28 |
| 2020-08-31 | $0.00 10-K · filed 2021-11-29 |
| 2019-08-31 | $0.00 10-K · filed 2020-10-15 |
| 2018-08-31 | $1.82M 10-K · filed 2019-11-14 |
| 2017-08-31 | $0.00 10-K · filed 2018-11-14 |
| 2016-08-31 | $0.00 10-K · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |